Asterand Bioscience acquired by BioIVT in 2017
Asterand Bioscience was a leading, global provider of high quality, well-characterized human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advanced drug research by accelerating target identification and biomarker validation and improving drug candidate selection to increase the likelihood of clinical success.
The acquisition of Asterand Bioscience occurred in August 2017 and expanded BioIVT's portfolio of highly-annotated, disease-state tissue specimens. By combining Asterand Bioscience's first-rate oncology tissue sourcing network with our existing strength in procuring disease-state tissue and clinical biofluids, BioIVT became the market leader in disease-state biospecimens, and a top resource for researchers focused on precision medicine. The addition of Asterand Bioscience's tissue services and PHASEZERO® research services groups allowed the combined company the ability to offer a full research workflow solution, ranging from specimen sourcing through experimental design and data collection. BioIVT's new offerings included target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.
Read the full release for more details about the Asterand acquisition.